Stephen Glover
Chief Executive Officer at ZYVERSA THERAPEUTICS, INC.
Net worth: 266 251 $ as of 2024-03-30
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Daniel O'Connor | M | 59 |
Ambrx Biopharma, Inc.
Ambrx Biopharma, Inc. BiotechnologyHealth Technology Ambrx Biopharma Cayman, Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA. | 2 years |
Kate Hermans | F | 56 |
Ambrx Biopharma, Inc.
Ambrx Biopharma, Inc. BiotechnologyHealth Technology Ambrx Biopharma Cayman, Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA. | 2 years |
Paul Maier | M | 76 |
Ambrx Biopharma, Inc.
Ambrx Biopharma, Inc. BiotechnologyHealth Technology Ambrx Biopharma Cayman, Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA. | 2 years |
Frank Bedu-Addo | M | 59 | 5 years | |
Sonja Nelson | F | 51 |
Ambrx Biopharma, Inc.
Ambrx Biopharma, Inc. BiotechnologyHealth Technology Ambrx Biopharma Cayman, Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA. | 3 years |
Janet Loesberg | M | 61 |
Ambrx Biopharma, Inc.
Ambrx Biopharma, Inc. BiotechnologyHealth Technology Ambrx Biopharma Cayman, Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA. | 2 years |
Denny Lanfear | M | 68 | 17 years | |
Jared Kelly | M | - |
Ambrx Biopharma, Inc.
Ambrx Biopharma, Inc. BiotechnologyHealth Technology Ambrx Biopharma Cayman, Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA. | 1 years |
Margaret Dalesandro | M | 77 |
Ambrx Biopharma, Inc.
Ambrx Biopharma, Inc. BiotechnologyHealth Technology Ambrx Biopharma Cayman, Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA. | 1 years |
Gregory Freitag | M | 62 | 5 years | |
Min-Chul Park | M | 42 |
ZyVersa Therapeutics Operating, Inc.
ZyVersa Therapeutics Operating, Inc. Pharmaceuticals: MajorHealth Technology ZyVersa Therapeutics Operating, Inc. operates as a specialty pharmaceutical company, which develops and commercializes prescription pharmaceutical products. The firm focuses on developing products for the treatment of men?s health, as well as for other markets where current therapies are suboptimal and underdeveloped. It offers VAR 100, an oral formulation of native testosterone to treat male hypogonadism; and VAR 200 that minimizes and prevents kidney cell damage, and improves focal segmental glomerulosclerosis prognosis. The company was founded by Stephen C. Glover and Shawn M. Titcomb in 2014 and is headquartered in Weston, FL. | 2 years |
Xiaowei Chang | M | 41 |
Ambrx Biopharma, Inc.
Ambrx Biopharma, Inc. BiotechnologyHealth Technology Ambrx Biopharma Cayman, Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA. | 9 years |
Robert Finizio | M | 53 |
ZyVersa Therapeutics Operating, Inc.
ZyVersa Therapeutics Operating, Inc. Pharmaceuticals: MajorHealth Technology ZyVersa Therapeutics Operating, Inc. operates as a specialty pharmaceutical company, which develops and commercializes prescription pharmaceutical products. The firm focuses on developing products for the treatment of men?s health, as well as for other markets where current therapies are suboptimal and underdeveloped. It offers VAR 100, an oral formulation of native testosterone to treat male hypogonadism; and VAR 200 that minimizes and prevents kidney cell damage, and improves focal segmental glomerulosclerosis prognosis. The company was founded by Stephen C. Glover and Shawn M. Titcomb in 2014 and is headquartered in Weston, FL. | 6 years |
Shawn Zhang | M | - | - | |
Andrew Aromando | M | 55 |
Ambrx Biopharma, Inc.
Ambrx Biopharma, Inc. BiotechnologyHealth Technology Ambrx Biopharma Cayman, Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA. | 1 years |
Ying Buechler | M | - | 6 years | |
Kamil Ali-Jackson | F | 65 | 4 years | |
James Sapirstein | M | 63 | 1 years | |
Steven Gerst | M | - |
Asclepius Life Sciences Fund LP
Asclepius Life Sciences Fund LP Financial ConglomeratesFinance Asclepius Life Sciences Fund LP provides pooled investment funds. The company was founded by Stephen C. Glover and Steven Gerst and is headquartered in New York, NY. | - |
Peter Wolfe | M | 56 | 2 years | |
Mats Wahlström | M | 70 | 12 years | |
Richard Sykes | M | 79 | 5 years | |
Otis Brawley | M | 64 | 4 years | |
Lars Robert Boesgaard | M | 55 | 1 years | |
David Schaaf | M | - | 2 years | |
Janice Lu | M | - |
Ambrx Biopharma, Inc.
Ambrx Biopharma, Inc. BiotechnologyHealth Technology Ambrx Biopharma Cayman, Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA. | 2 years |
Dennis Van | M | - |
Wallace H. Coulter Foundation
| - |
Spencer Brown | M | 54 | 2 years | |
Sandra Aung | M | - | 1 years | |
Richard Ferrari | M | 70 |
Wallace H. Coulter Foundation
| - |
Jakob Dupont | M | 58 | 3 years | |
Gregory Conn | M | 69 | 19 years | |
Ilian Iliev | M | 48 | 4 years | |
Renu Vaish | F | - |
Ambrx Biopharma, Inc.
Ambrx Biopharma, Inc. BiotechnologyHealth Technology Ambrx Biopharma Cayman, Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA. | 1 years |
Karen Cashmere | F | 71 | 2 years | |
Pablo Guzman | M | 74 | 1 years | |
Stephen Snowdy | M | 55 |
Wallace H. Coulter Foundation
| - |
Walter R. Perkins | M | - | 14 years | |
Joe J. Dervan | M | - | - | |
Kirk Shepard | M | - | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Katrin Rupalla | M | 56 |
Ambrx Biopharma, Inc.
Ambrx Biopharma, Inc. BiotechnologyHealth Technology Ambrx Biopharma Cayman, Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA. | 2 years |
Deanne Randolph | F | - | - | |
Donald Hayden | M | 68 | 9 years | |
Andrew Saik | M | 54 | 1 years | |
Allison Tomek | F | 48 |
Andrx Corp.
Andrx Corp. Pharmaceuticals: MajorHealth Technology Andrx Corp. developed, manufactured, and marketed oral pharmaceutical products. The company was founded in August, 1992 and was headquartered in Davie, FL. | 3 years |
James J. Loughlin | M | 81 | - | |
Nicholas Lee Gurreri | M | - | - | |
Alan C. Herman | M | 76 | - | |
Jules Müsing | M | 76 |
ZyVersa Therapeutics Operating, Inc.
ZyVersa Therapeutics Operating, Inc. Pharmaceuticals: MajorHealth Technology ZyVersa Therapeutics Operating, Inc. operates as a specialty pharmaceutical company, which develops and commercializes prescription pharmaceutical products. The firm focuses on developing products for the treatment of men?s health, as well as for other markets where current therapies are suboptimal and underdeveloped. It offers VAR 100, an oral formulation of native testosterone to treat male hypogonadism; and VAR 200 that minimizes and prevents kidney cell damage, and improves focal segmental glomerulosclerosis prognosis. The company was founded by Stephen C. Glover and Shawn M. Titcomb in 2014 and is headquartered in Weston, FL. | - |
Thomas Rice | M | 74 |
Andrx Corp.
Andrx Corp. Pharmaceuticals: MajorHealth Technology Andrx Corp. developed, manufactured, and marketed oral pharmaceutical products. The company was founded in August, 1992 and was headquartered in Davie, FL. | 3 years |
Dee Grosso | F | - | - | |
Stuart E. Builder | M | - | - | |
Nicholas LaBella | M | 68 | 4 years | |
Timothy G. Whitten | M | 67 | 2 years | |
Kevin P. Tully | M | 70 | 6 years | |
Vladimir Vexler | M | 66 | 10 years | |
W. Middlekauff | M | 63 | - | |
Geoffrey Allan | M | 70 | 10 years | |
Matthew Hill | M | 56 | 2 years | |
Seth van Voorhees | M | 63 | - | |
Scott Lodin | M | 68 |
Andrx Corp.
Andrx Corp. Pharmaceuticals: MajorHealth Technology Andrx Corp. developed, manufactured, and marketed oral pharmaceutical products. The company was founded in August, 1992 and was headquartered in Davie, FL. | 11 years |
DeLyle Bloomquist | M | 65 | 7 years | |
Douglas H Farrar | M | - | - | |
Christos Richards | M | 66 | 9 years | |
Paul D'Angio | M | 65 | 1 years | |
Michael P. King | M | - | 1 years | |
Janetta Trochimiuk | F | 61 | - | |
Hillary Yegen | F | - | - | |
Richard J. Lane | M | - |
Andrx Corp.
Andrx Corp. Pharmaceuticals: MajorHealth Technology Andrx Corp. developed, manufactured, and marketed oral pharmaceutical products. The company was founded in August, 1992 and was headquartered in Davie, FL. | 1 years |
Peter K. Watler | M | 62 | - | |
Lauren Wood | M | 64 | 5 years | |
Deepa Prasad | F | 44 | 2 years | |
Nathalie Riebel | F | - | 4 years | |
Renu Gupta | M | 68 | 4 years | |
Ian J. Watkins | M | 61 |
Andrx Corp.
Andrx Corp. Pharmaceuticals: MajorHealth Technology Andrx Corp. developed, manufactured, and marketed oral pharmaceutical products. The company was founded in August, 1992 and was headquartered in Davie, FL. | 3 years |
Michael Nazak | M | 66 | 6 years | |
Kenneth G. Condon | M | 76 | 11 years | |
Hemanshu N. Pandya | M | 52 |
Andrx Corp.
Andrx Corp. Pharmaceuticals: MajorHealth Technology Andrx Corp. developed, manufactured, and marketed oral pharmaceutical products. The company was founded in August, 1992 and was headquartered in Davie, FL. | 1 years |
John Malcolm Hanson | M | 71 |
Andrx Corp.
Andrx Corp. Pharmaceuticals: MajorHealth Technology Andrx Corp. developed, manufactured, and marketed oral pharmaceutical products. The company was founded in August, 1992 and was headquartered in Davie, FL. | 2 years |
Thomas Keuer | M | 65 | 2 years | |
Philip Young | M | 66 | 3 years | |
Eric Richman | M | 63 |
ZyVersa Therapeutics Operating, Inc.
ZyVersa Therapeutics Operating, Inc. Pharmaceuticals: MajorHealth Technology ZyVersa Therapeutics Operating, Inc. operates as a specialty pharmaceutical company, which develops and commercializes prescription pharmaceutical products. The firm focuses on developing products for the treatment of men?s health, as well as for other markets where current therapies are suboptimal and underdeveloped. It offers VAR 100, an oral formulation of native testosterone to treat male hypogonadism; and VAR 200 that minimizes and prevents kidney cell damage, and improves focal segmental glomerulosclerosis prognosis. The company was founded by Stephen C. Glover and Shawn M. Titcomb in 2014 and is headquartered in Weston, FL. | 2 years |
Graham K. Crooke | M | 65 | 11 years | |
Ronald D. Gunn | M | 63 | 9 years | |
Matthew R. Hooper | M | 66 | - | |
Laura Edgerly-Pflug | F | 60 | 7 years | |
S. Torres | M | 61 | 3 years | |
Kenneth Attie | M | 67 | 3 years | |
Barbara Finck | M | 77 | 10 years | |
Anthony Giovinazzo | M | 67 |
ZyVersa Therapeutics Operating, Inc.
ZyVersa Therapeutics Operating, Inc. Pharmaceuticals: MajorHealth Technology ZyVersa Therapeutics Operating, Inc. operates as a specialty pharmaceutical company, which develops and commercializes prescription pharmaceutical products. The firm focuses on developing products for the treatment of men?s health, as well as for other markets where current therapies are suboptimal and underdeveloped. It offers VAR 100, an oral formulation of native testosterone to treat male hypogonadism; and VAR 200 that minimizes and prevents kidney cell damage, and improves focal segmental glomerulosclerosis prognosis. The company was founded by Stephen C. Glover and Shawn M. Titcomb in 2014 and is headquartered in Weston, FL. | - |
August Troendle | M | 67 | 6 years | |
Nicholas F. Cappuccino | M | - |
Andrx Corp.
Andrx Corp. Pharmaceuticals: MajorHealth Technology Andrx Corp. developed, manufactured, and marketed oral pharmaceutical products. The company was founded in August, 1992 and was headquartered in Davie, FL. | - |
Eric Pallokat | M | - |
Andrx Corp.
Andrx Corp. Pharmaceuticals: MajorHealth Technology Andrx Corp. developed, manufactured, and marketed oral pharmaceutical products. The company was founded in August, 1992 and was headquartered in Davie, FL. | 5 years |
Sanjay Zaveri | M | - | 2 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 94 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Stephen Glover
- Personal Network